Press Releases

 
 
December 19, 2023 07:30 ET|Knight Therapeutics
MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an…
 
Knight Therapeutics Reports Third Quarter 2023 Results
November 09, 2023 07:30 ET|Knight Therapeutics
MONTREAL, Nov. 09, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial…
Notice of Knight Therapeutics’ Third Quarter 2023 Results Conference Call
November 02, 2023 07:30 ET|Knight Therapeutics
MONTREAL, Nov. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2023…
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in Brazil
October 16, 2023 07:30 ET|Knight Therapeutics
MONTREAL, Oct. 16, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,…
Knight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
October 10, 2023 16:45 ET|Knight Therapeutics
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc., (TSX: GUD) (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate,…
Knight Therapeutics Inc. places No. 90 on The Globe and Mail’s fifth-annual ranking of Canada’s Top Growing Companies
October 02, 2023 16:30 ET|Knight Therapeutics
MONTREAL, Oct. 02, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it placed No. 90 on the 2023 Report on Business ranking of Canada’s…
Knight Therapeutics Reports Second Quarter 2023 Results
August 10, 2023 07:30 ET|Knight Therapeutics
MONTREAL, Aug. 10, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial…
Notice of Knight Therapeutics’ Second Quarter 2023 Results Conference Call
August 03, 2023 20:32 ET|Knight Therapeutics
MONTREAL, Aug. 03, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2023…
Knight Announces Normal Course Issuer Bid
July 12, 2023 07:30 ET|Knight Therapeutics
MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company “),  a leading pan-American (ex-US) specialty pharmaceutical company, announced today…

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue

You are now leaving the Knight Canada website and entering other country website where the information presented may have different labeling than in Canada, and the Canadian Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Click here to continue